Medicare has approved coverage for obesity drugs from Novo Nordisk and Eli Lilly.
Steady: 0 in the last 7 days
Updated oct 7
The latest in this situation
How it started
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Medicare has approved coverage for obesity drugs from Novo Nordisk and Eli Lilly.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Medicare signed deals with drug makers and Trump announced a new program.1 source
Medicare coverage expansion is driving patient volume for Eli Lilly products amid intense GLP-1 competition.1 source
- Novo Nordisk launched oral Wegovy in the U.S. while Medicare set co-pays for the bridge program, alongside soaring sales for Eli Lilly's drugs.Sub-event
Medicare coverage approved for obesity drugs from Novo Nordisk and Eli Lilly.1 source
Keep exploring
The entities involved
-
Novo Nordisk
Danish pharmaceutical company
-
Eli Lilly and Company
American pharmaceutical company
-
Medicare
US federal health insurance
Related events
- Novo Nordisk and Astellas Pharma are noted as large-cap healthcare companies, with Novo Nordisk reporting higher revenue and earnings.
- Eli Lilly and Novo Nordisk are competing for market share in the weight loss drug sector.
- Bristol-Myers Squibb and Novo Nordisk are noted as competitors in the healthcare sector.
- Medicare coverage is driving growth in the obesity drug market, leading to raised price targets for Eli Lilly.